MADRID, Spain—Adding evolocumab (Repatha; Amgen) to statin therapy does not lower the risk of saphenous vein graft (SVG) failure among patients who undergo coronary artery bypass surgery, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback